The designation is supported by data from the 12-week, randomized, double-blind phase 2 FILLMORE trial. The Food and Drug Administration (FDA) has granted Orphan Drug designation to AMT-101 for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback